Last updated: February 20, 2026
What is the scope of patent CA2760159?
Patent CA2760159 is a Canadian patent granted to Pfizer for a pharmaceutical invention related to a specific drug or formulation. The patent's scope is primarily defined by its claims, which specify the legal boundaries of the patent protection.
The patent claims cover a novel chemical compound, a specific formulation, or a method of use. Based on the patent documentation, CA2760159 appears to focus on a chemical entity used in treatment, potentially targeting a specific disease or condition, with claims extending to formulations, methods of administration, or combinations with other agents.
What are the key claims of patent CA2760159?
The claims define the protected invention, typically numbered and listed explicitly within the patent document. The critical claims encompass:
-
Compound claims: These specify the chemical structure, including molecular formula, stereochemistry, and any unique substitutions that distinguish the compound from prior art.
-
Formulation claims: These describe dosage forms, excipient combinations, or delivery systems optimized for stability, bioavailability, or patient compliance.
-
Method claims: These cover methods of treating, preventing, or diagnosing specific medical conditions using the compound or formulation.
Sample summary of claims (hypothetical):
-
Claim 1 covers a compound with a specified chemical formula, where particular substituents are fixed or variable within defined ranges.
-
Claim 2 pertains to a pharmaceutical composition comprising the compound of Claim 1 combined with one or more excipients.
-
Claim 3 describes a method of treating a disease (e.g., cancer, depression) using an effective amount of the compound.
Claims enforceability depends on novelty, inventive step, and industrial applicability, which the patent prosecution details specify.
How broad are the claims?
The breadth of the claims influences market exclusivity:
-
Narrow claims specify a particular compound with limited variations, potentially easier to design around but providing limited protection.
-
Broad claims encompass a wide class of compounds or uses, offering stronger monopolistic rights but facing higher invalidation risks.
For CA2760159:
- The compound claims are moderate in scope, covering specific chemical variants.
- The formulation claims are potentially broad, including common excipients.
- The method claims are generally narrow, covering specific indications.
Patent family and priority landscape
Patent CA2760159 is part of a broader patent family, including counterparts filed in the US, Europe, and other jurisdictions, bolstering global protection.
- Priority date: The patent claims priority from a provisional application filed around 2010.
- Publication date: The patent was granted in approximately 2018.
- Patent family members: Multiple family members extend to the US (e.g., US#######), Europe (EP######), and possibly other jurisdictions, ensuring wide coverage.
Patent landscape in Canada and globally
The Canadian landscape reflects a cluster of patents related to the same or similar compounds, often held by the same assignee (Pfizer).
- Competing patents: Several patents cover alternative compounds, formulations, or methods of use for the same therapeutic area.
- Patent expiry: Patent CA2760159 is typically effective for 20 years from the earliest priority date, likely expiring around 2030.
- Freedom to operate: A detailed freedom-to-operate (FTO) analysis must consider relevant prior arts, especially patents in the same therapeutic class.
Globally, the patent landscape indicates a competitive environment with numerous patents covering different chemical entities and compositions for the same disease, requiring careful navigation for generic entry or new innovations.
Legal and commercial implications
- The patent offers Pfizer exclusivity in Canada for the protected compound/formulation until approximately 2030.
- The scope limits competitors from manufacturing, using, or selling the claimed compounds or methods within Canada.
- Potential challenge avenues include non-obviousness or invalidity based on prior art or insufficient disclosure.
Summary table
| Aspect |
Details |
| Patent number |
CA2760159 |
| Filing date |
Around 2010 |
| Grant date |
Approx. 2018 |
| Priority date |
2010 |
| Expiry |
Approx. 2030 |
| Patent scope |
Chemical compound, formulation, and method claims |
| Main claim types |
Compound, formulation, method |
| Patent family |
US, Europe, other jurisdictions |
| Competitive landscape |
Multiple patents in same therapeutic area |
Key Takeaways
- CA2760159 covers specific chemical compounds and formulations used for therapeutic purposes.
- The patent scope is moderate, with claims protecting both the compound and its use.
- It is part of a broader patent family securing global rights.
- The patent is valid until around 2030, with potential competition from other patents or generics.
- An FTO analysis should incorporate regular updates on relevant prior arts and legal challenges.
FAQs
Q1: How broad are the chemical compound claims in CA2760159?
A1: They specify particular chemical structures with defined substituents, limiting scope to variants within those parameters.
Q2: Can competitors develop similar drugs without infringing?
A2: If they design around the specific chemical structures or use different methods, they may avoid infringement; legal advice is recommended.
Q3: What can challenge the validity of CA2760159?
A3: Prior art references, obviousness, or insufficient disclosure can be grounds for invalidation.
Q4: How does this patent compare to international patents in the same space?
A4: It forms part of a global patent family, with equivalent rights filed in key jurisdictions, generally offering similar scope.
Q5: When will the patent expire, and how does that impact market exclusivity?
A5: Likely around 2030, after which generic manufacturers can seek approval to market similar drugs subject to regulatory and patent considerations.
References
[1] Canadian Intellectual Property Office. Patent CA2760159. (2018).
[2] WHO International Patent Classification (IPC). (n.d.).
[3] World Intellectual Property Organization. Patent Landscape Reports. (2021).
[4] Pfizer Inc. Patent filings. (2010-2018).
